Nodular Prurigo Market Revenue Expected to Reach $1.59 Billion by 2029

 Grab 20% Off With Code ONLINE20 On Global market Reports — Evaluate Global Trends, Market Risks, and Competitive Intelligence

 

 How Has the Nodular Prurigo Market Evolved in Terms of Size and Value From 2025 to 2029?
 The nodular prurigo market size has grown strongly in recent years. It will grow from $1.17 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to rising dermatology consultations, increased awareness among dermatologists, unmet medical need, academic research focus and improvements in diagnostic techniques.
 
 The nodular prurigo market size is expected to see strong growth in the next few years. It will grow to $1.6 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to the approval of targeted therapies, increased r&d funding for rare dermatologic conditions, stronger patient advocacy and awareness campaigns, health insurance and reimbursement expansion and companion diagnostics and biomarker development. Major trends in the forecast period include AI-driven diagnostics, gene editing, nanotechnology in drug delivery, biologics innovation, and wearable monitoring devices.
 
 Get your free report sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=24624&type=smp
 
 Which Key Drivers Are Fueling Growth in the Nodular Prurigo Market?
 The increasing demand for targeted therapies is expected to propel the growth of the nodular prurigo market going forward. Targeted therapies refer to the medical treatments that specifically target and interfere with molecular pathways involved in the growth and spread of diseases. The rising demand for targeted therapies can be due to their ability to provide more precise treatments with fewer side effects, improving patient outcomes and offering alternatives to traditional, less specific therapies. Nodular prurigo helps drive the development of targeted therapies by presenting a clear unmet medical need involving specific immune pathways such as IL-4, IL-13, and IL-31, which enables the use of biologics that precisely block these inflammatory signals for more effective treatment. For instance, in October 2023, according to NHS England, a UK-based government agency, in England, 11 million hormone replacement therapy (HRT) items were prescribed, up 47% from 2021–22, with around 2.3 million patients receiving prescriptions, marking a 29% year-on-year increase. Therefore, the increasing demand for targeted therapies is driving growth in the nodular prurigo market.
 
 What Are the Major Segments Defining the Structure of the Nodular Prurigo Market?
 The nodular prurigo market covered in this report is segmented — 
 
 1) By Type: Chronic Nodular Prurigo, Acute Nodular Prurigo, Subacute Nodular Prurigo
 2) By Treatment Type: Topical Treatments, Systemic Treatments, Phototherapy, Immunosuppressants
 3) By Patient Demographics: Adults, Children, Elderly
 4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users
 
 Subsegments:
 1) By Chronic Nodular Prurigo: Idiopathic Chronic Nodular Prurigo, Secondary To Dermatologic Conditions, Neuropathic Causes, Systemic Disease-Associated, Psychogenic Prurigo
 2) By Acute Nodular Prurigo: Insect Bite-Induced, Allergic Reactions, Drug-Induced Prurigo, Infectious Triggers
 3) By Subacute Nodular Prurigo: Healing Phase Of Chronic Prurigo, Post-Inflammatory Prurigo, Transient Dermatoses, Reaction To Environmental Irritants
 
 Which Major Trends Are Expected to Define the Nodular Prurigo Market Through 2029?
 Major companies operating in the nodular prurigo market are focusing on getting regulatory approvals to expand market reach and improve patient outcomes. Regulatory approvals refer to the formal authorization granted by governmental or regulatory bodies for a drug, medical device, or treatment to be marketed and used by the public. For instance, in September 2022, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, received FDA approval for Dupixent (dupilumab), the first and only treatment specifically indicated for prurigo nodularis in adults. This approval was based on data from two pivotal Phase 3 trials (PRIME and PRIME2), which demonstrated that Dupixent significantly reduced itch and skin lesions compared to placebo. Dupixent became the only medicine in the U.S. with an approved indication for treating prurigo nodularis, addressing a substantial unmet medical need for approximately 75,000 adults affected by the condition in the U.S.
 
 Which Key Players Dominate the Nodular Prurigo Market Landscape?
 Major companies operating in the nodular prurigo market are Merck & Co Inc., Sanofi S.A., GlaxoSmithKline plc, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Galderma S.A., Galderma Laboratories L.P. , Incyte Corporation, Kyowa Kirin Co Ltd., LEO Pharma A/S, Maruho Co Ltd., Kiniksa Pharmaceuticals Ltd., Keymed Biosciences Co Ltd., Trevi Therapeutics Inc., Fierce Pharma, Menlo Therapeutics Inc., VYNE Therapeutics Inc., Celldex Therapeutics Inc. 
 
 Get the detailed nodular prurigo market report today
 https://www.thebusinessresearchcompany.com/report/nodular-prurigo-global-market-report
 
 Which Region Is Expected to Dominate the Nodular Prurigo Market During the Forecast Period?
 North America was the largest region in the nodular prurigo market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nodular prurigo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company: https://thebusinessresearchcompany.com/ 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 Email: info@tbrc.info 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company